Form HLTH5489 Special Authority Request - Benralizumab / Mepolizumab - British Columbia, Canada

Form HLTH5489 Special Authority Request - Benralizumab / Mepolizumab - British Columbia, Canada

The Form HLTH5489 Special Authority Request - Benralizumab/Mepolizumab is used in British Columbia, Canada to request special approval for the use of the medications Benralizumab or Mepolizumab. These medications are used for the treatment of certain respiratory conditions, such as severe asthma. The form is used to assess patient eligibility for coverage and funding for these medications.

The Special Authority Request Form HLTH5489 is typically filed by healthcare professionals, such as doctors or specialists, on behalf of their patients in British Columbia, Canada.

FAQ

Q: What is the HLTH5489 Special Authority Request?
A: The HLTH5489 Special Authority Request is a form that needs to be completed to request coverage for the medications Benralizumab or Mepolizumab.

Q: What are Benralizumab and Mepolizumab?
A: Benralizumab and Mepolizumab are medications used for the treatment of severe eosinophilic asthma.

Q: Who can use the HLTH5489 Special Authority Request form?
A: The form is specifically for residents of British Columbia, Canada.

Q: What is special authority?
A: Special authority is a process used by the government to determine if a medication will be covered by public or private insurance plans.

Q: Why would someone need to request special authority for Benralizumab or Mepolizumab?
A: Special authority may be required for these medications because they are expensive, and the government wants to ensure they are being prescribed appropriately and used for conditions approved for coverage.

Q: What information is required to complete the HLTH5489 Special Authority Request?
A: The form requires personal information, medical history, details about previous treatments, and supporting documentation from a healthcare provider.

Q: How long does it take to process a special authority request for Benralizumab or Mepolizumab?
A: The processing time can vary, but it typically takes several weeks to receive a decision.

Q: What happens if my special authority request is approved?
A: If your request is approved, the medications Benralizumab or Mepolizumab may be covered by your insurance plan.

Q: What happens if my special authority request is denied?
A: If your request is denied, you may need to explore other options for accessing these medications, such as private insurance or patient assistance programs.

Q: Are there any fees associated with submitting the HLTH5489 Special Authority Request?
A: There are no fees to submit the form.

Q: Can I appeal a denied special authority request?
A: Yes, there is an appeals process available if your request is denied.

ADVERTISEMENT

Download Form HLTH5489 Special Authority Request - Benralizumab / Mepolizumab - British Columbia, Canada

4.8 of 5 (25 votes)
  • Form HLTH5489 Special Authority Request - Benralizumab/Mepolizumab - British Columbia, Canada

    1

  • Form HLTH5489 Special Authority Request - Benralizumab/Mepolizumab - British Columbia, Canada, Page 2

    2

  • Form HLTH5489 Special Authority Request - Benralizumab / Mepolizumab - British Columbia, Canada, Page 1
  • Form HLTH5489 Special Authority Request - Benralizumab / Mepolizumab - British Columbia, Canada, Page 2
Prev 1 2 Next
ADVERTISEMENT

Related Documents